# 4D Molecular Therapeutics, Inc. FDMT

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001650648

**B**

**second fifth of 370 graded peers in healthcare**

rank 92 of 370; percentile 24.7; sampling error 2.5 points; lower is stronger

A B C D E

**B, the elk**



## Scoreboard

| | |
|---|---|
| **Profitability** | C/D<br>percentile 59.4 |
| **Solvency** | B<br>percentile 30.0 |
| **Growth and financing** | B<br>percentile 30.9 |
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $566.7M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution, short runway<br>not computable: fortress balance sheet |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Mar 18, 2026<br>234 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026 |
| **Last close** | $12.24<br>2026-11-06; market equity $675.8M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 18, 2026*

We are a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with the potential to transform treatment paradigms and provide unprecedented benefits to patients. Our products are developed with customized and evolved adeno-associated virus ("AAV") vectors invented from our proprietary vector discovery platform, Therapeutic Vector Evolution ("TVE") which was designed to generate vectors with properties that overcome the limitations of conventional AAV vectors.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 59.4** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (5.5%) | (6.6%) | 59.4 | 802 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 30.0** | | | | | |
| Twelve-month failure probability | 0.13% | 0.08% | 58.1 | 249 | 2026-06-30 |
| Altman Z double-prime | 6.96 | (0.37) | 14.2 | 747 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 9.39x | 2.94x | 17.8 | 828 | 2025-12-31 |
| **Growth and financing, sleeve percentile 30.9** | | | | | |
| Revenue growth, three-year compound | 200.9% | 10.0% | 1.7 | 412 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *one or more required annual facts are missing* | | | | | |
| Asset growth, three years | 29.4% | 2.2% | 15.5 | 696 | 2025-12-31 |
| Net share issuance, one year | 49.8% | 2.5% | 75.4 | 630 | 2024-02-23 |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 49.8% |
| Short runway | cash runway is 5.4 months |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 87 | Warby Parker Inc. (WRBY) | 23.3 | B | |
| 88 | Amphastar Pharmaceuticals, Inc. (AMPH) | 23.6 | B | |
| 89 | Guardant Health, Inc. (GH) | 23.8 | B | |
| 90 | Cronos Group Inc. (CRON) | 24.1 | B | |
| 91 | Sarepta Therapeutics, Inc. (SRPT) | 24.4 | B | |
| 92 | 4D Molecular Therapeutics, Inc. (FDMT) | 24.7 | B | dilution, short runway |
| 93 | Pulmonx Corp. (LUNG) | 24.9 | B | fortress balance sheet |
| 94 | NeuroPace Inc. (NPCE) | 25.2 | B | |
| 95 | Rhythm Pharmaceuticals, Inc. (RYTM) | 25.5 | B | short runway |
| 96 | GE HealthCare Technologies Inc. (GEHC) | 25.7 | B | |
| 97 | Mannatech Inc. (MTEX) | 26.0 | B | late filer, fortress balance sheet |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-11-06 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 24.4% | (2.1%) | 66 |
| Distance from 52-week high | (26.9%) | (30.5%) | 53 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | (16.2%) | (1.0%) | 26 |
| Book value to price | 0.60 | 0.29 | 75 |
| Sales to price | 0.13 | 0.30 | 31 |
| Composite equity issuance, five years | not computable | 21.4% | |
| Relative strength against the sector, log excess return | 0.05 | (0.19) | 66 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $70.4M |
| Operating cash flow, four quarters | -$156.1M |
| Months of runway | 5.4 |
| Days since last periodic filing | 86 (10-Q received Aug 13, 2026) |
| Median daily dollar volume, 63 sessions | $12.0M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$140.1M | 2025-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$109.1M | 2025-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 3 | assets | us-gaap:Assets | $566.7M | 2025-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 4 | assets | us-gaap:Assets | $560.4M | 2024-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 5 | current assets | us-gaap:AssetsCurrent | $413.1M | 2025-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $44.0M | 2025-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$716.3M | 2025-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$159.5M | 2025-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 9 | book equity | us-gaap:StockholdersEquity | $505.7M | 2025-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 10 | liabilities | us-gaap:Liabilities | $61.0M | 2025-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $85.2M | 2025-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $37,000 | 2024-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $20.7M | 2023-12-31 | 2025-02-28 | 10-K | 25-030056 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $3.1M | 2022-12-31 | 2024-02-29 | 10-K | 24-023183 |
| 15 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $536,000 | 2025-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 16 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$134.6M | 2024-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $3.8M | 2024-12-31 | 2026-03-18 | 10-K | 26-114075 |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$75.8M | 2023-12-31 | 2025-02-28 | 10-K | 25-030056 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $2.8M | 2023-12-31 | 2025-02-28 | 10-K | 25-030056 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$86.7M | 2022-12-31 | 2024-02-29 | 10-K | 24-023183 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $11.5M | 2022-12-31 | 2024-02-29 | 10-K | 24-023183 |
| 22 | assets | us-gaap:Assets | $339.9M | 2023-12-31 | 2025-02-28 | 10-K | 25-030056 |
| 23 | assets | us-gaap:Assets | $261.8M | 2022-12-31 | 2024-02-29 | 10-K | 24-023183 |
| 24 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 49,778,127 | 2024-02-23 | 2024-02-29 | 10-K | 24-023183 |
| 25 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 33,234,357 | 2023-03-08 | 2023-03-15 | 10-K | 23-008142 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.